Pfizer made the announcement based on the interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) study that evaluated the efficacy of Paxlovid .
PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19
In the overall …
Pfizer has announced the results of its Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) interim analysis, revealing
VT’s medical team has samples to ship of Avifavir, possibly as effective or more than Pfizers new drug…much less expensive…approved now in 12 countries. However, read this and read the detailed statement below. Be informed. Daily Beast: Pfizer’s new antiviral pill dramatically reduces the chances of getting seriously sick or dying from COVID-19 if it’s […]